Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 13/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 3/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.47 |
| ▸ | TUBB | P07437 | 5/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5614582 | 1.00 | TUBB1 (0.61) | TUBB1PTGS1PTGS2NQO2TUBB4A | |
| SCHEMBL7175444 | 1.00 | TUBB1 (0.61) | TUBB1PTGS1PTGS2NQO2TUBB4A | |
| SCHEMBL14649633 | 0.87 | PTGS1 (0.50) | TUBB1PTGS1PTGS2NQO2TUBB4A | |
| SCHEMBL14649585 | 0.87 | PTGS1 (0.50) | TUBB1PTGS1PTGS2NQO2TUBB4A | |
| SCHEMBL31266997 | 0.82 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6710989 | 0.80 | GAA (0.44) | TUBB1PTGS1PTGS2NQO2TUBB4A | |
| SCHEMBL6323762 | 0.80 | ABCG2 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6009804 | 0.78 | ABCG2 (0.63) | — | |
| SCHEMBL12677608 | 0.77 | TUBB4A (0.59) | TUBB1NQO2TUBB4ATUBBTUBA3C | |
| SCHEMBL6456490 | 0.77 | TUBB4A (0.59) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853270-B2 | Substituted stilbenes and their reactions | UNIVERSITY OF SALFORD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20130023663-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | HADFIELD JOHN ANTHONY (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20070203217-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) | 2007-08-30 | — | — | US | disclosed |
| US-20070203217-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) | 2007-08-30 | — | — | US | disclosed |
| US-7220784-B2 | Substituted stilbenes and their reactions | CANCER RESEARCH VENTURES LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| US-7220784-B2 | Substituted stilbenes and their reactions | CANCER RESEARCH VENTURES LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | CANCER RESEARCH VENTURES LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1351912-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | Cancer Research Ventures Limited (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002050007-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023663-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | BLVRB, BBOX1, SQLE | TUBB1 1121/4885PTGS1 1432/4885PTGS2 2077/4885 |
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | QPCT, PAM, AURKB | TUBB1 1455/4885PTGS1 1512/4885PTGS2 2112/4885 |
| US-20070203217-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | CASP4, ATG4B, CTSB | TUBB1 1146/4885PTGS1 1404/4885PTGS2 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.